Scope of this report
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Research and analysis highlights
Array BioPharma is an early-stage biopharmaceutical company that is engaged in the development and commercialization of pharmaceutical products for oncology and inflammatory disease indications.
The company has six investigational drug candidates in clinical programs, namely, ARRY-543 (Phase I), ARRY-797 (Phase II), ARRY-520 (Phase I), ARRY-380 (Preclinical)
Array BioPharma derives its revenues mainly creating, optimizing, evaluating and developing drug candidates for its collaborators. The company recognizes revenues related to collaborations with other companies such as AstraZeneca, Roche and Eli Lilly etc. for co-developing product candidates and out-licensing chemical compounds.
Key reasons to read this report
Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization
Table of Contents
Overview
Catalyst
Summary
Table of Contents
Table of figures
Table of tables
Company Structure
Company Overview and Key Facts
Business Description
Landmark Products and Services
Array Discovery Platform
History
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Geographic Segment Performance
Products & Services
Pipeline Products
In-house Pipeline
ARRY-543
ARRY-797
ARRY-520
ARRY-380
ARRY-614
ARRY-162
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Array Discovery Platform
Strategic alliances and collaborations
Weaknesses
Expected decline in revenues
Opportunities
Out-licensing opportunities
Growing cancer and inflammatory disease markets
Threats
E arly-stage product pipeline
Industry consolidation
Value Chain Analysis
Discovery and Product Development
Manufacturing
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Robert E. Conway
Kevin Koch
David L. Snitman
Kyle A. Lefkoff
Francis J. Bullock
Marvin H. Caruthers
Gil J. Van Lunsen
Douglas E. Williams
John L. Zabriskie
R. Michael Carruthers
John Yates
John R. Moore
John A. Josey
James D. Winkler
Financial and Operational Overview
APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer
List of Figures
Figure 1: Array BioPharma - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
For more information kindly visit: http://www.bharatbook.com/
